Tufts' poll probes social media in trials; Illumina talks genomics data bottlenecks;

> A Tufts survey found 20% of biopharma firms have contacted a patient directly on social media. Article

> Illumina's ($ILMN) president warned data management is an obstacle to genomics-powered improvements to cancer care. Piece

> Merge Healthcare ($MRGE) committed to creating a data center in Brazil after winning a contract with CRO Eurotrials. News

> Deloitte added the Regenstrief Institute to its real-world evidence and analytics consortium. Post

> Advanced Biological Laboratories started selling its genome data analysis tool, OncoChek. Release

> HCL Technologies renewed a contract with Purdue Pharma. Item

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.